ESGO 2021 | ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer

Mansoor Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses ENGOT-EN1: a randomized placebo-controlled Phase II trial (NCT02730416) of carboplatin and paclitaxel plus nintedanib, a tyrosine kinase inhibitor, for patients with advanced or recurrent endometrial cancer. No benefit was found with the addition of nintedanib, with the primary endpoint of progression-free survival not being met. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.